Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05797688
Other study ID # 15586
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date December 2016
Est. completion date September 2017

Study information

Verified date December 2016
Source Winthrop University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to determine whether autologous, adipose-derived regenerative cells improve the healing of chronic wounds. Ten patients will undergo fat harvest and peri-wound injection of the isolated cells in addition to the standard of care for the treatment of their chronic wound. Wound healing will be followed over 24 weeks.


Description:

This study will be an open-label, preliminary, proof-of-concept trial. Ten patients will undergo debridement of their wound per the standard of care currently offered by Winthrop University Hospital along with concurrent fat harvest according to the standard protocols of the Winthrop University Hospital Plastic surgeons. The harvested fat will be immediately processed using an automated system to isolate regenerative cells, including stem cells. This will be followed by same-day subcutaneous injection of the isolated cells into the debrided wound site. The patients will then undergo weekly wound debridements according to the current standard of care treatment protocols. They will be followed weekly for 24 weeks in the outpatient wound clinic and observed for pain, erythema of the injection site, wound infection, edema, fever, bleeding and wound healing as measured by wound size and area. Fat harvest and subcutaneous injection will be repeated 3 months after the initial procedure if the wound has not decreased in size by at least 40%. Patients can undergo a maximum of 2 cycles of fat harvest and cell injection.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2017
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject must agree to adhere to all protocol procedures and return for weekly scheduled wound assessment visits, including requirements for taking and abstaining from medications. 2. Subject is willing and able to read, understand and sign a written Informed Consent to participate in the study or have an appropriate representative available to do so. 3. Subject must have a full thickness Stage III or Stage IV pressure ulcer, deep venous ulcer, deep diabetic ulcer, ischemic ulcer, abdominal wound, nonhealing surgical site or sickle cell ulcer. For subjects with more than one wound that meet these criteria, the largest qualifying wound will be treated. 4. Subject has adequate (>200 mL) abdominal or other subcutaneous adipose tissue accessible by syringe-based fat harvest and is able to undergo a fat harvest procedure in the opinion of the investigator or per facility guidelines and has activated platelet thromboplastin time (aPTT) within the normal reference range at the time of the fat harvest procedure and no contraindication to fat harvest. 5. Subject's wound has been refractory to standard of care (no objective/measureable signs of healing) for at least 30 days. Exclusion Criteria: 1. Subject has local infection with erythema > 2 cm, or involving structures deeper than skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic arthritis, fasciitis), or associated with local wound complications such as prosthetic materials or protruding surgical hardware. 2. Subject has = 2 of the following signs of systemic inflammatory response syndrome (SIRS) or septic shock within 7 days of screening: - Temperature > 38°C or < 36°C - Heart rate > 90 beats/min - Respiratory rate > 20 breaths/min or PaCO2 < 32 mm Hg - White blood cell count > 12,000 or < 4,000 cells/µL or = 10% immature (band) forms. 3. Subject has received biologic or cell therapy within 12 weeks of initiation of the study. 4. Subject not eligible for syringe-based liposuction of at least 200 mL of subcutaneous adipose tissue, including therapeutic anticoagulation with INR >1.7 or PTT >60, or receiving GIIb/IIIa inhibitors within 2 weeks prior to the study. 5. Subject has squamous cell carcinoma, basal cell carcinoma, melanoma or skin carcinoma of the affected limb or area and underwent treatment within the last year. 6. Subject is pregnant as determined by a positive pregnancy test prior to procedure, or breast-feeding. 7. Clinically significant abnormal findings on laboratory screening panels, including hemoglobin =10 g/dL. 8. Hepatic dysfunction, as defined as aspartate aminotransferase (AST), alanine aminotranferase (ALT), or bilirubin level > 1.5 times the upper limit of normal range (x ULN) prior to randomization. 9. Chronic renal insufficiency as defined as a serum creatinine > 2.0 mg/dL or requires dialysis. 10. History of organ transplantation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
The Celution System
The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.

Locations

Country Name City State
United States Winthrop University Hospital Mineola New York

Sponsors (2)

Lead Sponsor Collaborator
Winthrop University Hospital Cytori Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety as assessed by weekly evalutation of the occurrence of wound infection, redness, swelling, pain, fever, chills, bleeding, and wound healing. 1 year
Secondary Complete wound healing Wounds will be evaluated for 100% epithelialization with no drainage. 1 year
Secondary Time to healing The time when complete healing occurs will be recorded, up to 1 year. 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Active, not recruiting NCT03649308 - Negative Pressure Wound Therapy Compared to Traditional Care After Skin Grafting N/A
Active, not recruiting NCT03796988 - Autologous Regeneration of Tissue (ART) for Wound Healing N/A
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT05588583 - A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing. N/A
Suspended NCT01301118 - Graft Take and Microbiology in Burns N/A
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Completed NCT03938584 - The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients N/A
Not yet recruiting NCT05324514 - Microscopic Skin Tissue Column Grafting Technique Using the Autologous Regeneration of Tissue System N/A
Recruiting NCT05608317 - A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing N/A
Recruiting NCT05844527 - Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients Phase 2
Completed NCT04771819 - Safety and Performance of SWIS in Superficial Wounds N/A
Active, not recruiting NCT05263713 - Aesthetic Outcome of Running Subcuticular Suture Versus Running Horizontal Mattress Suture Closure of Linear Wounds on the Trunk and Extremities N/A
Recruiting NCT05741866 - Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs) N/A
Completed NCT01348841 - Wound Interdisciplinary Teams (WIT): A Community- Based Pragmatic Randomized Controlled Trial N/A
Recruiting NCT05217160 - Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers Phase 4
Recruiting NCT03346694 - Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing N/A
Completed NCT03481907 - Topical Collagen Powder for Healing of Acute Full-thickness Wounds N/A
Completed NCT01658163 - Use of 2-octyl-cyanoacrylate Together With a Self-adhering Mesh N/A
Recruiting NCT06178289 - Effectiveness of 3M Cavilon Advanced Skin Protectant in the Treatment of Moisture-associated Skindamage in Nursinghomes N/A